Transgene (XPAR:TNG) PensionAndRetirementBenefit : €2.77 Mil (As of Dec. 2024)

View and export this data going back to 1998. Start your Free Trial

What is Transgene PensionAndRetirementBenefit?

Transgene's PensionAndRetirementBenefit for the quarter that ended in Dec. 2024 was €2.77 Mil.

Transgene's quarterly PensionAndRetirementBenefit declined from Dec. 2023 (€3.35 Mil) to Jun. 2024 (€3.13 Mil) and declined from Jun. 2024 (€3.13 Mil) to Dec. 2024 (€2.77 Mil).

Transgene's annual PensionAndRetirementBenefit increased from Dec. 2022 (€3.28 Mil) to Dec. 2023 (€3.35 Mil) but then declined from Dec. 2023 (€3.35 Mil) to Dec. 2024 (€2.77 Mil).

Transgene PensionAndRetirementBenefit Historical Data

The historical data trend for Transgene's PensionAndRetirementBenefit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Transgene PensionAndRetirementBenefit Chart

Transgene Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

PensionAndRetirementBenefit

Get a 7-Day Free Trial

4.06

3.96

3.28

3.35

2.77

Transgene Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
PensionAndRetirementBenefit	Get a 7-Day Free Trial															3.28	3.15	3.35	3.13	2.77

Transgene PensionAndRetirementBenefit Calculation

PensionAndRetirementBenefit is the carrying amount as of the balance sheet date of the portion of the obligations recognized for the various benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement.

Transgene Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Transgene SA (XPAR:TNG) » Definitions » PensionAndRetirementBenefit

Comparable Companies

Traded in Other Exchanges

TRGNF:USA 0OCQ:UK TGNA:Germany

Address

400, Boulevard Gonthier d’Andernach, Parc d’Innovation, Illkirch-Graffenstaden, Strasbourg, FRA, 67400

Website

https://www.transgene.fr

Transgene SA is a biotechnology company that designs and develops targeted immunotherapy products for cancer. Transgene's programs utilize viral vector technology with the goal of indirectly or directly killing infected or cancerous cells. The company's portfolio of products in clinical development includes TG4050, an individualized therapeutic vaccine based on the myvac platform, TG4001, a therapeutic vaccine for HPV positive cancers, as well as BT-001 and TG6050, two oncolytic viruses based on the Invir.IO viral backbone. Transgene has several other programs in clinical and pre-clinical development that are based on its core viral vector technology. Geographically, the majority of its operations are located in France.

Transgene Headlines

No Headlines